FDA Drops the Hammer on Twitter

The FDA just announced new regulations for pharma and biotech companies that wish to promote their drugs via Twitter (Nasdaq: TWTR). Companies cannot brag about a drugs benefits without also tweeting about the associated risks of taking it. There aren't a lot of companies currently promoting in 140 characters, but given clear guidlines we could see an increase in sponsored tweets.

In this episode of Market Check-Up, the Motley Fool's health care focused investing show, analysts David Williamson and Michael Douglass, discuss the new FDA regs, why stocks like Ariad (Nasdaq: ARIA) and VIVUS (Nasdaq: VVUS) will have trouble in this new medium, and the most likely to use this new marketing avenue. Watch and find out.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 23, 2014, at 7:50 AM, gazoo99 wrote:

    VVUS can't afford any advertising anyhow...

    Twiter is simply a cheap way to premote it's drug without paying much....Now that door will be closed.

    If they had to tweet Qysmia's side effects...there would be no room for anything else.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3003488, ~/Articles/ArticleHandler.aspx, 8/31/2015 2:02:49 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

David Williamson

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated Moments ago Sponsored by:
DOW 16,551.51 -91.50 -0.55%
S&P 500 1,976.89 -11.98 -0.60%
NASD 4,802.01 -26.31 -0.54%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 1:46 PM
ARIA $9.29 Down -0.60 -6.07%
Ariad Pharmaceutic… CAPS Rating: ***
ARNA $2.74 Up +0.03 +0.92%
Arena Pharmaceutic… CAPS Rating: **
TWTR $28.14 Up +1.31 +4.88%
Twitter CAPS Rating: ***
VVUS $1.14 Down -0.01 -0.87%
VIVUS, Inc. CAPS Rating: **